More patients and an improved response rate might once again shift the sentiment on Constellation Pharmaceuticals and its contentious drug for myelofibrosis — this time in a positive direction.
With 63 myelofibrosis patients now treated and evaluable in the company’s mid-stage study, the 24-week spleen response rate to its oral drug, CPI-0610 — when used on top of Jakafi, Incyte’s market-leading drug — stands at 67%. The new data were presented Saturday at the annual meeting of the American Society of Hematology.
The previous update from this study was in June, based on 30 evaluable patients. The response at that time had fallen to 63%, raising some concern about CPI-0610’s future.
About the Author Reprints
